-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
HER2 is a predictive biomarker for HER2 targeted therapy
Here, the authors report a positive correlation between the early endosomal marker RAB5A and T-DM1 sensitivity in 5 HER2 positive cell lines
The increasing attention to personalized medicine and our growing knowledge of cancer biology have revealed the great potential of biomarkers in cancer treatment
HER2 (ERBB2) is a proven biomarker for breast cancer.
The ability of HER2 to accept receptor-mediated endocytosis also makes this transmembrane protein a candidate protein for delivering cytotoxic agents to cancer cells
After administration, T-DM1 binds to HER2 and enters cells through HER2-mediated endocytosis
Correlation between T-DM1 and RAB GTPase in the I-SPY2 cohort
Image source: https://doi.
The mechanism of action of T-DM1 is obviously more complicated than that of HER2 targeting mAbs and TKIs, and the authors have assessed whether this is reflected in biomarkers that can be used to predict drug response
In this work, the authors report the correlation between T-DM1 treatment response and RAB5A expression levels
Note: The original text has been deleted
references
Olav Engebraaten et al.
